PLSE Key Statistics, Chart & Performance
The current stock price of PLSE is 14.25 USD. In the past month the price decreased by -0.07%. In the past year, price decreased by -19.08%.
PLSE Technical Analysis
PLSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLSE. PLSE has a great financial health rating, but its profitability evaluates not so good.
PLSE Financial Highlights
Over the last trailing twelve months PLSE reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS decreased by -40.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.71% | ||
| ROE | -80.62% | ||
| Debt/Equity | 0 |
PLSE Forecast & Estimates
7 analysts have analysed PLSE and the average price target is 22.44 USD. This implies a price increase of 57.47% is expected in the next year compared to the current price of 14.25.
PLSE Ownership
PLSE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.4 | 211.72B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.14 | 189.66B | ||
| SYK | STRYKER CORP | 27.62 | 139.12B | ||
| BSX | BOSTON SCIENTIFIC CORP | 29.85 | 130.56B | ||
| BDX | BECTON DICKINSON AND CO | 14.36 | 59.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.73 | 57.12B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.82 | 48.95B | ||
| RMD | RESMED INC | 26.02 | 37.60B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.81 | 37.24B | ||
| DXCM | DEXCOM INC | 37.39 | 27.12B | ||
| PODD | INSULET CORP | 62.95 | 20.24B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.79 | 17.30B |
Related stock screener links
About PLSE
Company Profile
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Company Info
PULSE BIOSCIENCES INC
3957 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Darrin R. Uecker
Employees: 75
Phone: 15109064600
PULSE BIOSCIENCES INC / PLSE FAQ
What does PLSE do?
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
What is the current price of PLSE stock?
The current stock price of PLSE is 14.25 USD. The price increased by 1.06% in the last trading session.
Does PULSE BIOSCIENCES INC pay dividends?
PLSE does not pay a dividend.
What is the ChartMill rating of PULSE BIOSCIENCES INC stock?
PLSE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for PULSE BIOSCIENCES INC?
PULSE BIOSCIENCES INC (PLSE) will report earnings on 2026-03-25.
Can you provide the short interest for PLSE stock?
The outstanding short interest for PULSE BIOSCIENCES INC (PLSE) is 14.68% of its float.